Alder Edge? Platform: Value- Add of Cogentia’s Landscape Assessment?

During the Alder Edge? landscape assessment for both target therapy areas, Cogentia provided a range of modules tailored to Alder’s core objectives of supporting direction-setting that would support future fund raising.??

These individual modules were:?

1. Landscape assessment: Involved a deep dive into the specific landscape of each scope market, ensuring an in-depth understanding of unmet needs to evaluate the relative commercial opportunity of both ALD01 and ALD02, and a comprehensive grasp of the competitive environment to gage potential positioning for Alder Edge?.??

1. Target product profile (TPP) development: Development of a clear and strategic TPP for each therapy area was pivotal to define the characteristics and requirements of the Alder Edge? platform to meet market demands effectively, and shape commercial planning.??

1. Market value drivers: Identification and dissection of the critical factors which shape a market’s value ensured an appreciation of the factors which drive success within both target landscapes.??

1. Forecast model development and support: Construction of a robust forecast model provided reliable commercial predictions for Alder Edge? and insights into future market dynamics.?

1. Pricing assumptions: Explored and formulated pricing assumptions for Alder Edge? in each scope market, allowing Alder to make informed decisions relating to product pricing in alignment with current market trends.?

These modules provided valuable insights and were synthesised into a strong rationale regarding the value and potential targets, and where to focus the Alder Edge? platform. Cogentia identified specific indication targets, evaluated them, and provided directional validation and quantification.? Future options outside of the existing scope could be to quantify the platform’s overall value.?

Whilst our landscape assessment mainly focused on the long-term commercial opportunities and the core value drivers of Alder Edge?, our insights also provided support for initial clinical development, of which the first-in-human clinical trials are expected in 2026.?

Successful Commercialisation: The Value of Early Market Access Strategy Planning?

Integrating a market access perspective from the outset optimises the probability of commercial success. A platform technology’s innovative and scientific capabilities are undoubtedly vital, but they also must align with the practical realities of market dynamics, healthcare systems, and patient requirements to both get the funding and to become a commercial success.??

We would recommend that technology developers understand which market they are targeting, it’s dynamics, the route to market, reimbursement structures, funding, regulatory pathways and competitive landscapes, pricing and where used, all of which influence the platform’s commercial viability and sustainability. Ignoring this perspective can result in time and money invested in sub- optimal development, which may hinder the platform’s success.??

So, What’s Next for Alder Therapeutics???

Following Cogentia’s inputs, Alder Therapeutics stated that the landscape assessment provided belief in the commercial potential of the two programmes, assisting their decision to choose the ALD01 programme as a lead and providing pricing aspects to aid development.?

Alder Therapeutics also stated that the early value strategy provided has enabled the communication of Alder Edge’s commercial potential, allowing the technology to be much more visible to potential investors. In addition, Alder Therapeutics have clarified their development plan up until market launch, and now are aware of the potential financial benefits expected once this milestone is reached.?

However, Alder Therapeutics’ journey is more than a recount of current and future milestones. It serves as proof of their dedication to push the boundaries of medical innovation, enhancing patient outcomes, and maintaining a commitment to providing patients with easy access to pluripotent stem cell therapy treatments via their Alder Edge? platform. The integration of an early market access perspective from Cogentia into the Alder Edge? platform’s development has been a pivotal component of Alder Therapeutics’ journey and is an essential step to maximising the potential for commercial success in the future.?

To learn more about Alder Therapeutics and the Alder Edge? platform, please visit their website at https://www.aldertx.com/.?

Cogentia’s Services Span Across Every Stage of a Product’s Lifecycle?

Our comprehensive range of market access services offers an integrated approach designed to seamlessly enhance the value throughout every stage of a platform or product’s lifecycle, as exemplified in our collaboration with @Alder Therapeutics for this post. Whether you are envisioning the next genome editing breakthrough or are developing a revolutionary cell therapy platform, we’ve got you covered.?

It is worth emphasising that no two platforms or technologies are the same. We encourage our clients to engage in open discussions with us to ensure their needs are communicated effectively. Our projects are fully customisable to your specific requirements, whether that involves the selection of particular modules or opting for specific markets, of which we have expertise across a wide array of global markets.?

Below is an illustration of the following modules and elements which are often useful during the development of platform technologies.?

For more information about our offerings, please visit our website: https://cogentia.co.uk/?

#marketaccess #consulting #platform #pluripotent #stemcell??